Group 1 - The A-share market saw a significant decline in innovative drug concept stocks, with notable drops including Aidi Pharmaceutical down over 11% and Yifang Bio down over 5% [1] - Other companies such as Xingqi Pharmaceutical, Zhenbaodao, and Dize Pharmaceutical experienced declines of over 4%, while Rongchang Bio, Hanshang Group, Yuekang Pharmaceutical, Xinlitai, Haishike, Shanghai Yizhong, and Kanghong Pharmaceutical fell by over 3% [1] Group 2 - Aidi Pharmaceutical (688488) reported a decline of 11.33%, with a total market value of 7.835 billion and a year-to-date increase of 14.02% [2] - Yifang Bio (688382) decreased by 5.99%, with a market capitalization of 15 billion and a year-to-date decline of 4.99% [2] - Xingqi Pharmaceutical (300573) fell by 4.82%, with a market value of 19.4 billion and a year-to-date increase of 12.01% [2] - Zhenbaodao (603567) dropped by 4.74%, with a market capitalization of 7.951 billion and a year-to-date decline of 5.38% [2] - Dize Pharmaceutical (688192) decreased by 4.19%, with a market value of 27.5 billion and a year-to-date increase of 2.78% [2] - Rongchang Bio (688331) fell by 3.98%, with a market capitalization of 56.1 billion and a year-to-date increase of 27.79% [2] - Hanshang Group (600774) decreased by 3.93%, with a market value of 3.101 billion and a year-to-date increase of 14.99% [2] - Yuekang Pharmaceutical (688658) dropped by 3.84%, with a market capitalization of 12 billion and a year-to-date increase of 18.40% [2] - Xinlitai (002294) fell by 3.32%, with a market value of 55.5 billion and a year-to-date increase of 0.48% [2] - Haishike (002653) decreased by 3.23%, with a market capitalization of 56.1 billion and a year-to-date decline of 2.44% [2] - Shanghai Yizhong (688091) dropped by 3.17%, with a market value of 11.2 billion and a year-to-date increase of 15.60% [2] - Kanghong Pharmaceutical (002773) fell by 3.15%, with a market capitalization of 29.5 billion and a year-to-date increase of 6.81% [2]

1月22日，益方生物跌5.01%，截至发稿，报26.15元/股，成交2.66亿元，换手率2.38%，总市值151.24亿 元。益方生物股价已经连续3天下跌，区间累计跌幅8.66%。 资料显示，益方生物科技(上海)股份有限公司位于中国(上海)自由贸易试验区李冰路67弄4号210室,香港 湾仔皇后大道东183号合和中心46楼，成立日期2013年1月11日，上市日期2022年7月25日，公司主营业 务涉及创新药物的研发、生产和销售。主营业务收入构成为：技术授权和技术合作收入100.00%。 从益方生物十大流通股东角度 中欧国证2000指数增强A（018663）成立日期2023年7月18日，最新规模5718.92万。今年以来收益 9.12%，同类排名1461/5542；近一年收益45.01%，同类排名1564/4256；成立以来收益51.71%。 中欧国证2000指数增强A（018663）基金经理为钱亚婷、宋婷。 截至发稿，钱亚婷累计任职时间4年82天，现任基金资产总规模59.26亿元，任职期间最佳基金回报 85.19%， 任职期间最差基金回报-14.61%。 宋婷累计任职时间336天，现任基金资产总规模31.32亿 ...

1月21日，AI主线强势回归，截至14:20，科创人工智能ETF汇添富(589560)放量上涨3.00%， 反包前两日跌幅！ | 序号 | 代码 | 名称 | 申万一级行业 | 涨跌幅 | 估買板車 ▼ | | --- | --- | --- | --- | --- | --- | | 1 | 688521 | 芯原股份 | 电子 | 4.60% | 11.11% | | 2 | 688008 | 澜起科技 | 电子 | 10.92% | 9.99% | | 3 | 688111 | 金山办公 | 计算机 | -0.39% | 9.43% | | 4 | ୧୫୫25୧ | 寒武纪-U | 电子 | 1.11% | 8.34% | | ਦੇ | 688169 | 石头科技 | 家用电器 | 0.41% | 5.12% | | 6 | 688099 | 脂膏胺役 | 曲子 | 1.65% | 4.99% | | 7 | 688568 | 中科营图 | 计算机 | -1.78% | 4.90% | | 8 | ୧୫8382 | 复旦微电 | 电子 | 1.98% | 4.89% | | 9 | 688608 | 恒 ...

Core Viewpoint - The A-share market is experiencing fluctuations, particularly affecting the innovative drug sector, with the ETF Huatai Innovation Drug (589120) declining by 2.05% and facing a five-day losing streak, despite attracting over 7.9 million yuan in funds [1][3]. Group 1: Market Performance - The Huatai Innovation Drug ETF (589120) has seen a decline in its constituent stocks, with major players like I-Mab and Junshi Biosciences dropping over 3%, and others like BeiGene and Zai Lab falling more than 2% [3]. - The top ten constituent stocks of the ETF show a negative trend, with BeiGene-U down by 2.38% and Junshi Biosciences-U down by 3.42%, indicating a general downturn in the sector [3]. Group 2: Long-term Outlook - Despite the short-term market pressure, the long-term outlook for the innovative drug sector remains positive, with expectations of a clear beta market driven by liquidity recovery at the beginning of the year [4]. - The JPM conference highlighted the achievements of over 20 Chinese pharmaceutical companies, with projections for significant revenue growth in innovative drugs, such as a 25% increase for Heng Rui in 2026 [4]. Group 3: Business Development (BD) Trends - The BD activities in the sector are at a peak, with 17 transactions occurring since January, totaling approximately 10.15 billion USD in upfront payments, significantly exceeding market expectations [5]. - The ongoing trend of foreign companies expanding in China and the increasing flow of funds into the innovative drug sector suggest a favorable environment for growth and investment [5]. Group 4: Investment Strategy - The innovative drug sector is recommended for increased allocation, particularly in Hong Kong stocks, as the market is currently at a relative bottom, with potential for new historical highs [5]. - The ETF focuses on leading innovative drug companies, providing a high degree of exposure to the opportunities presented by the rise of Chinese innovative drugs [5].

证券代码：688382 证券简称：益方生物 公告编号：2026-003 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 160,715,196股。 本次股票上市流通总数为160,715,196股。 本次股票上市流通日期为2026 年 1 月 26 日。 益方生物科技（上海）股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 4 月 1 日出具的《关于同意益方生物 科技（上海）股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕682 号），同意益方生物科技（上海）股份有限公司（以下简称"公司"）首次公开发 行股票的注册申请。公司首次向社会公众公开发行人民币普通股（A 股）股票 115,000,000 股，并于 2022 年 7 月 25 日在上海证券交易所科创板上市，发行完成 后总股本为 575,000,000 股，其中有限售条件流通股 475,506,983 股 ...

中信证券股份有限公司 关于益方生物科技（上海）股份有限公司 首次公开发行部分限售股上市流通的核查意见 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 4 月 1 日出具的《关于同意益方生 物科技（上海）股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕 682 号），同意益方生物科技（上海）股份有限公司（以下简称"公司"）首次公 开发行股票的注册申请。公司首次向社会公众公开发行人民币普通股（A 股）股 票 115,000,000 股，并于 2022 年 7 月 25 日在上海证券交易所科创板上市，发行 完成后总股本为 575,000,000 股，其中有限售条件流通股 475,506,983 股，无限售 条件流通股 99,493,017 股。 本次上市流通的限售股为公司首次公开发行部分限售股，限售期为自公司首 次公开发行股票并在科创板上市之日起 42 个月。限售股东 5 名，对应的股份数 量为 160,715,196 股，占公司总股本的比例为 27.79%，具体内容详见公司于 2022 年 8 月 27 日披露于上海证券交易所网站（www.sse.com.cn）及指定媒体的 ...

（记者 张明双） 每经头条（nbdtoutiao）——白银50天涨逾80%，疯狂程度远超黄金，历史上爆炒白银往往预示贵金属 牛市已到高潮，这次有何不同？ 每经AI快讯，益方生物1月16日晚间发布公告称，公司限售股份约1.61亿股将于2026年1月26日解禁并上 市流通，占公司总股本比例为27.79%。 ...

格隆汇1月16日｜益方生物公告称，本次上市流通的限售股为首次公开发行部分限售股，数量为 160,715,196股，占公司总股本的27.79%，将于2026年1月26日起上市流通。自限售股形成至公告披露 日，公司因激励计划归属股份，总股本由5.75亿股变为5.78亿股。此外，公司控股股东、实际控制人、 董监高等对所持股份锁定作出承诺。保荐人认为，本次限售股上市流通符合相关法规要求，无异议。 ...

据港交所文件： 益方生物 科技（上海）股份有限公司- B向港交所提交上市申请书。 ...

据港交所文件：益方生物科技（上海）股份有限公司 - B向港交所提交上市申请书。 ...